Navigation Links
The Quantum Group Extends CEO's Employment Agreement
Date:3/28/2008

Secures full ownership of patent pending technologies

WELLINGTON, Fla., March 28 /PRNewswire-FirstCall/ -- The Quantum Group, Inc. (Amex: QGP, QGP.WSA, QGP.WSB) (http://www.QuantumMD.com) announced today that the Board of Directors and Noel J. Guillama, Quantum founder, President and Chief Executive Officer; have reached an agreement to amend his existing employment agreement to, among other things, extend his term of employment with the Company. The terms of the agreement are described in the Company's Current Report on Form 8-K filed on March 28, 2008.

Dr. Jose de la Torre, Chairman of the Compensation and Options Committee of The Quantum Group Board of Directors, commented, "We are thrilled to have reached this agreement which secures the continued leadership of Noel Guillama for Quantum. His vision, dedication, and experience established the Company five years ago and remain the catalyst for the continued progress of the organization."

Mr. Guillama further commented, "I am happy to receive this vote of confidence from our Board of Directors and expect that I will spend the peak of my professional years building this Company which I truly believe will be the changing force in the healthcare industry. Having previously built one of the healthcare industry leaders in the state of Florida, my personal goal has evolved to build the largest Company in this sector in Florida in the next decade."

The Company further announced that it has received full ownership of a number of recently filed provisional business process patents previously developed by Mr. Guillama.

About The Quantum Group, Inc.

The Quantum Group is a Florida-based organization. The Company builds and manages healthcare systems and offers consulting and outsourcing services to the nation's largest and fastest growing industry- healthcare.

The Company is leveraging leading-edge technology wit
'/>"/>

SOURCE The Quantum Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. The Quantum Group Announces 1st Quarter Financial Results for Fiscal Year 2008
2. The Quantum Group Announces Strategic Technology Alliance
3. The Quantum Group to Present at the Jesup & Lamont Emerging Growth Stock Conference on February 28th
4. The Quantum Group Reports 4th Quarter and Year End Results for Fiscal Year 2007
5. The Quantum Group, Inc. Announces Separation of Units
6. Results promising for computational quantum chemical methods for drug development
7. The Quantum Group, Inc. Completes $13.2 Million Public Offering and Initiates Trading on the American Stock Exchange Under Symbol QGP
8. American Stock Exchange Lists the Common Stock and Units of The Quantum Group, Inc.
9. Quantum Foundation Makes a Half Million Dollars Available to Federally Qualified Health Centers
10. Quantum light beams good for fast technology
11. Texas Senator Kirk Watson Honored as Champion for Children by the AMERIGROUP Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10DSS Research Announces Senior Health Risk Assessment 28SrHRA 29 28TM 29 58537 1DSS Research Announces Senior Health Risk Assessment 28SrHRA 29 28TM 29 58537 2Pan American Life Insurance Group Plans to Complete Coverage in Central America With Entry Into Costa Rica 3B Company Files Request for Authorization 58534 1Pan American Life Insurance Group Plans to Complete Coverage in Central America With Entry Into Costa Rica 3B Company Files Request for Authorization 58534 2Sport Science Lab Maintains That Injury to USC Football Player is Symptomatic of the Dangers of Conventional Weight Training 58530 1Sport Science Lab Maintains That Injury to USC Football Player is Symptomatic of the Dangers of Conventional Weight Training 58530 2